Botulinum neurotoxin-a for treatment of refractory neck pain: A randomized, double-blind study

Diana Miller, Diana Richardson, Mahmood Eisa, Rizma Jalees Bajwa, Bahman Jabbari

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Objective: To investigate the efficacy and tolerability of Botulinum neurotoxin-A (BoNT-A) in the patients with refractory neck pain.Background: An analgesic effect is suggested for BoNT-A by a number of animal studies. Two blinded studies suggested efficacy of BoNT-A in a chronic neck pain.Methods: Forty-seven subjects were enrolled in a prospective, double-blind, placebo-controlled study. A total of 150 to 300 units of BoNT-A were injected into the neck and shoulder muscles based on pain localization. Subjects completed the visual analog scale (VAS), Pain Frequency Questionnaire and the Modified Oswestry Pain Questionnaire (MOPQ) at baseline, 3 and 8 weeks after the treatment. The primary outcomes consisted of: 1) ≥50% improvement on the VAS; and 2) ≥30% reduction in pain day frequency. The secondary outcome was an improvement of ADL in MOPQ. Excellent responders (ERs) were those who met all three outcomes.Results: At 2 months, a significant reduction in the mean VAS (pain intensity) was noted in the BoNT-A group compared with the placebo (P = 0.0018, CI 95% from 2.51 to 7.89). At 2 months, there were six ERs in the BoNT-A group and one ER in the placebo group (P = 0.0152).Conclusion: Administration of BoNT-A into the neck and shoulder muscles for treatment of chronic refractory neck pain met one of the two primary outcomes: reduction in pain intensity. More ERs were noted in the Botox group.

Original languageEnglish (US)
Pages (from-to)1012-1017
Number of pages6
JournalPain Medicine
Volume10
Issue number6
DOIs
StatePublished - Sep 1 2009

Fingerprint

Intractable Pain
Type A Botulinum Toxins
Neck Pain
Neurotoxins
Double-Blind Method
Pain
Neck Muscles
Placebos
Pain Measurement
Chronic Pain
Therapeutics
Activities of Daily Living
Visual Analog Scale
Analgesics

Keywords

  • Botulinum neurotoxin-A
  • Neck
  • Outcome measures
  • Persistent pain
  • Placebo

ASJC Scopus subject areas

  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this

Botulinum neurotoxin-a for treatment of refractory neck pain : A randomized, double-blind study. / Miller, Diana; Richardson, Diana; Eisa, Mahmood; Bajwa, Rizma Jalees; Jabbari, Bahman.

In: Pain Medicine, Vol. 10, No. 6, 01.09.2009, p. 1012-1017.

Research output: Contribution to journalArticle

Miller, Diana ; Richardson, Diana ; Eisa, Mahmood ; Bajwa, Rizma Jalees ; Jabbari, Bahman. / Botulinum neurotoxin-a for treatment of refractory neck pain : A randomized, double-blind study. In: Pain Medicine. 2009 ; Vol. 10, No. 6. pp. 1012-1017.
@article{f9314943da8a4b75adb6f08a618a631f,
title = "Botulinum neurotoxin-a for treatment of refractory neck pain: A randomized, double-blind study",
abstract = "Objective: To investigate the efficacy and tolerability of Botulinum neurotoxin-A (BoNT-A) in the patients with refractory neck pain.Background: An analgesic effect is suggested for BoNT-A by a number of animal studies. Two blinded studies suggested efficacy of BoNT-A in a chronic neck pain.Methods: Forty-seven subjects were enrolled in a prospective, double-blind, placebo-controlled study. A total of 150 to 300 units of BoNT-A were injected into the neck and shoulder muscles based on pain localization. Subjects completed the visual analog scale (VAS), Pain Frequency Questionnaire and the Modified Oswestry Pain Questionnaire (MOPQ) at baseline, 3 and 8 weeks after the treatment. The primary outcomes consisted of: 1) ≥50{\%} improvement on the VAS; and 2) ≥30{\%} reduction in pain day frequency. The secondary outcome was an improvement of ADL in MOPQ. Excellent responders (ERs) were those who met all three outcomes.Results: At 2 months, a significant reduction in the mean VAS (pain intensity) was noted in the BoNT-A group compared with the placebo (P = 0.0018, CI 95{\%} from 2.51 to 7.89). At 2 months, there were six ERs in the BoNT-A group and one ER in the placebo group (P = 0.0152).Conclusion: Administration of BoNT-A into the neck and shoulder muscles for treatment of chronic refractory neck pain met one of the two primary outcomes: reduction in pain intensity. More ERs were noted in the Botox group.",
keywords = "Botulinum neurotoxin-A, Neck, Outcome measures, Persistent pain, Placebo",
author = "Diana Miller and Diana Richardson and Mahmood Eisa and Bajwa, {Rizma Jalees} and Bahman Jabbari",
year = "2009",
month = "9",
day = "1",
doi = "10.1111/j.1526-4637.2009.00658.x",
language = "English (US)",
volume = "10",
pages = "1012--1017",
journal = "Pain Medicine",
issn = "1526-2375",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Botulinum neurotoxin-a for treatment of refractory neck pain

T2 - A randomized, double-blind study

AU - Miller, Diana

AU - Richardson, Diana

AU - Eisa, Mahmood

AU - Bajwa, Rizma Jalees

AU - Jabbari, Bahman

PY - 2009/9/1

Y1 - 2009/9/1

N2 - Objective: To investigate the efficacy and tolerability of Botulinum neurotoxin-A (BoNT-A) in the patients with refractory neck pain.Background: An analgesic effect is suggested for BoNT-A by a number of animal studies. Two blinded studies suggested efficacy of BoNT-A in a chronic neck pain.Methods: Forty-seven subjects were enrolled in a prospective, double-blind, placebo-controlled study. A total of 150 to 300 units of BoNT-A were injected into the neck and shoulder muscles based on pain localization. Subjects completed the visual analog scale (VAS), Pain Frequency Questionnaire and the Modified Oswestry Pain Questionnaire (MOPQ) at baseline, 3 and 8 weeks after the treatment. The primary outcomes consisted of: 1) ≥50% improvement on the VAS; and 2) ≥30% reduction in pain day frequency. The secondary outcome was an improvement of ADL in MOPQ. Excellent responders (ERs) were those who met all three outcomes.Results: At 2 months, a significant reduction in the mean VAS (pain intensity) was noted in the BoNT-A group compared with the placebo (P = 0.0018, CI 95% from 2.51 to 7.89). At 2 months, there were six ERs in the BoNT-A group and one ER in the placebo group (P = 0.0152).Conclusion: Administration of BoNT-A into the neck and shoulder muscles for treatment of chronic refractory neck pain met one of the two primary outcomes: reduction in pain intensity. More ERs were noted in the Botox group.

AB - Objective: To investigate the efficacy and tolerability of Botulinum neurotoxin-A (BoNT-A) in the patients with refractory neck pain.Background: An analgesic effect is suggested for BoNT-A by a number of animal studies. Two blinded studies suggested efficacy of BoNT-A in a chronic neck pain.Methods: Forty-seven subjects were enrolled in a prospective, double-blind, placebo-controlled study. A total of 150 to 300 units of BoNT-A were injected into the neck and shoulder muscles based on pain localization. Subjects completed the visual analog scale (VAS), Pain Frequency Questionnaire and the Modified Oswestry Pain Questionnaire (MOPQ) at baseline, 3 and 8 weeks after the treatment. The primary outcomes consisted of: 1) ≥50% improvement on the VAS; and 2) ≥30% reduction in pain day frequency. The secondary outcome was an improvement of ADL in MOPQ. Excellent responders (ERs) were those who met all three outcomes.Results: At 2 months, a significant reduction in the mean VAS (pain intensity) was noted in the BoNT-A group compared with the placebo (P = 0.0018, CI 95% from 2.51 to 7.89). At 2 months, there were six ERs in the BoNT-A group and one ER in the placebo group (P = 0.0152).Conclusion: Administration of BoNT-A into the neck and shoulder muscles for treatment of chronic refractory neck pain met one of the two primary outcomes: reduction in pain intensity. More ERs were noted in the Botox group.

KW - Botulinum neurotoxin-A

KW - Neck

KW - Outcome measures

KW - Persistent pain

KW - Placebo

UR - http://www.scopus.com/inward/record.url?scp=70349479057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349479057&partnerID=8YFLogxK

U2 - 10.1111/j.1526-4637.2009.00658.x

DO - 10.1111/j.1526-4637.2009.00658.x

M3 - Article

C2 - 19594841

AN - SCOPUS:70349479057

VL - 10

SP - 1012

EP - 1017

JO - Pain Medicine

JF - Pain Medicine

SN - 1526-2375

IS - 6

ER -